Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.2% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price was down 3.2% during trading on Tuesday . The company traded as low as $0.37 and last traded at $0.39. Approximately 45,372,542 shares were traded during trading, an increase of 52% from the average daily volume of 29,892,227 shares. The stock had previously closed at $0.40.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a report on Monday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Price Performance

The company’s 50 day simple moving average is $0.22 and its 200 day simple moving average is $0.41. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The stock has a market cap of $72.01 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. As a group, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.